SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    RiesLAG, SmithMA, GurneyJG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Besthesda: National Cancer Institute, 1999: 99110.
  • 2
    Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997; 44: 973989.
  • 3
    Grier HE. The Ewing family of tumors: Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am. 1997; 44: 9911004.
  • 4
    Rosen G, Caparros B, Groshen S. Primary osteogenic sarcoma of the femur: a model for the use of preoperative chemotherapy in high risk malignant tumors. Cancer Invest. 1984; 2: 181192.
  • 5
    Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremity. J Clin Oncol. 1993; 11: 17631769.
  • 6
    Meyers PA, Heller G, Healey JH, et al. Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial-Sloan Kettering experience. J Clin Oncol. 1992; 10: 515.
  • 7
    Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of non-metastastic osteosarcoma of the extremity with pre- and postoperative chemotherapy, CCG-782: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15: 7684.
  • 8
    Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993; 72: 32273238.
  • 9
    Smith J, Heelan RT, Huvos AG, et al. Radiographic changes in primary osteogenic sarcoma following intensive chemotherapy. Radiology. 1982; 143: 355360.
  • 10
    Murphy WA. Imaging bone tumors in the 1990's. Cancer. 1991; 67: 11691176.
  • 11
    Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000; 18: 16761688.
  • 12
    Schelling M, Avril N, Nährig J, et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000; 18: 16891695.
  • 13
    Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18] fluorodeoxyglucose positron emission tomography. Head Neck. 1997; 19: 666674.
  • 14
    Römer W, Hanauske A-R, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998; 91: 44644471.
  • 15
    Eary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18] fluorodeoxyglucose positron emission tomography in pretreatment evaluation and grading of sarcoma. Clin Cancer Res. 1998; 4: 12151220.
  • 16
    Folpe AL, Lyles RH, Sprouse JT, et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000; 6: 12791287.
  • 17
    Schuetze S, Conrad E, Bruckner J, et al. FDG PET response to neoadjuvant chemotherapy predicts survival in patients with soft tissue sarcoma [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 348a.
  • 18
    Miser J, Arndt C, Smithson W, et al. Treatment of high-grade osteosarcoma (OGS) with ifosfamide (IFOS), MESNA (MES), adriamycin (ADR), high-dose methotrexate (HDMTX), with or without cisplatin (CDDP); results of two pilot trials [abstract]. Proc Am Soc Clin Oncol. 1994; 13: 421a.
  • 19
    Meyers P, Schwartz C, Bernstein M, et al. Addition of ifosfamide and muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate improves event free survival (EFS) in localized osteosarcoma (OS) [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 367a.
  • 20
    Grier H, Krailo M, Link M, et al. Improved outcome in non-metastatic Ewing's sarcoma and PNET with the addition of ifosfamide and etoposide to vincristine, doxorubicin, cyclophosphamide and actinomycin D: a Children's Cancer (CCG) and Pediatric Oncology Group (POG) report [abstract]. Proc Am Soc Clin Oncol. 1994; 13: 421a.
  • 21
    Felgenhauer J, Hawkins D, Pendergrass T, et al. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas. Med Pediatr Oncol. 2000; 34: 2938.
  • 22
    Blaney SM, Seibel NL, O'Brien M, et al. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997; 15: 15381543.
  • 23
    Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma. Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977; 101: 1418.
  • 24
    Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15: 7684.
  • 25
    Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma. J Cancer Res Clin Oncol. 1983; 106 ( Suppl): 21–24.
  • 26
    Franzius C, Sciuk J, Brinkschmidt C, et al. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000; 25: 874881.
  • 27
    Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? Eur J Cancer. 1995; 31A: 19241995.
  • 28
    Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999; 35: 17731782.
  • 29
    Anderson H, Price P. What does positron emission tomography offer oncology? Eur J Cancer. 2000; 36: 20282035.
  • 30
    Stokkel MPM, Draisma A, Pauwels EKJ. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma. J Cancer Res Clin Oncol. 2001; 127: 278285.
  • 31
    Shulkin BL, Mitchell DS, Ungar DR, et al. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology. 1995; 194: 495500.
  • 32
    Jones DN, McGowage GB, Sostman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med. 1996; 37: 14381444.
  • 33
    Dehdashti F, Siegel BA, Griffeth LK, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology. 1996; 200: 243247.
  • 34
    Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999; 40: 16371643.
  • 35
    Hoekstra OS, Ossenkoppele GJ, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med. 1993; 34: 17061710.
  • 36
    Sumiya H, Taki J, Tsuchiya H, et al. Midcourse thallium-201 scintigraphy to predict tumor response in bone and soft-tissue tumors. J Nucl Med. 1998; 39: 16001604.
  • 37
    Imbriaco M, Yeh SDJ, Shang JJ, et al. Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma. Cancer. 1997; 80: 15071512.
  • 38
    Lin J, Leung W-T, Ho SKW, et al. Quantitative evaluation of thallium-201 uptake in predicting chemotherapeutic response of osteosarcoma. Eur J Nucl Med. 1995; 22: 553555.
  • 39
    Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994; 12: 26992705.
  • 40
    Cotterill SJ, Ahrens S, Pauluseen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18: 31083114.
  • 41
    Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteosarcoma: selection of postoperative adjuvant chemotherapy based upon the response of the primary tumor to preoperative therapy. Cancer. 1982; 49: 12211230.
  • 42
    Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based upon histological tumor response. J Clin Oncol. 1988; 6: 329337.
  • 43
    Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993; 72: 32273238.